Hydrogen sulfide attenuates spatial memory impairment and hippocampal neuroinflammation in beta-amyloid rat model of Alzheimer’s disease
© Xuan et al.; licensee BioMed Central Ltd. 2012
Received: 8 May 2012
Accepted: 4 August 2012
Published: 17 August 2012
Endogenously produced hydrogen sulfide (H2S) may have multiple functions in brain. An increasing number of studies have demonstrated its anti-inflammatory effects. In the present study, we investigated the effect of sodium hydrosulfide (NaHS, a H2S donor) on cognitive impairment and neuroinflammatory changes induced by injections of Amyloid-β1-40 (Aβ1-40), and explored possible mechanisms of action.
We injected Aβ1-40 into the hippocampus of rats to mimic rat model of Alzheimer’s disease (AD). Morris water maze was used to detect the cognitive function. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay was performed to detect neuronal apoptosis. Immunohistochemistry analyzed the response of glia. The expression of interleukin (IL)-1β and tumor necrosis factor (TNF)-α was measured by enzyme-linked immunosorbent assay (ELISA) and quantitative real-time polymerase chain reaction (qRT-PCR). The expression of Aβ1-40, phospho-p38 mitogen-activated protein kinase (MAPK), phospho-p65 Nuclear factor (NF)-κB, and phospho-c-Jun N-terminal Kinase (JNK) was analyzed by western blot.
We demonstrated that pretreatment with NaHS ameliorated learning and memory deficits in an Aβ1-40 rat model of AD. NaHS treatment suppressed Aβ1-40-induced apoptosis in the CA1 subfield of the hippocampus. Moreover, the over-expression in IL-1β and TNF-α as well as the extensive astrogliosis and microgliosis in the hippocampus induced by Aβ1-40 were significantly reduced following administration of NaHS. Concomitantly, treatment with NaHS alleviated the levels of p38 MAPK and p65 NF-κB phosphorylation but not JNK phosphorylation that occurred in the Aβ1-40-injected hippocampus.
These results indicate that NaHS could significantly ameliorate Aβ1-40-induced spatial learning and memory impairment, apoptosis, and neuroinflammation at least in part via the inhibition of p38 MAPK and p65 NF-κB activity, suggesting that administration of NaHS could provide a therapeutic approach for AD.
Alzheimer’s disease (AD) is a devastating and progressive neurodegenerative disorder characterized by extracellular deposition of Amyloid-β (Aβ) protein and intraneuronal neurofibrillary tangles (NFTs). Microglia have been implicated in the progressive nature of numerous neurodegenerative or neuroinflammatory diseases such as AD . The premise of deleterious microglial activation in AD has been supported by analysis of postmortem brains of patients with AD , where microglial over-activation occurred before neuropil damage, suggesting that it plays a causal role in the development of AD. The core of the senile plaque is the deposition of Aβ and the activated microglia and astroglia are around the senile plaque. In these glias, numerous inflammation factors including interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2), and so on, are overexpressed [3, 4]. Accumulating evidence indicates that neuroinflammatory processes may contribute to the pathophysiology of AD. However, traditional anti-inflammatory therapies such as non-steroidal anti-inflammatory drugs (NSAIDs) have produced mixed and conflicting results , highlighting the need for new and more specific anti-inflammatory targets.
Hydrogen sulfide (H2S) is best known as a poisonous gas with an extremely unpleasant odor. It is endogenously produced in the brain from cysteine by cystathionine β-synthase (CBS) and cystathione γ-lyase (CGL) . CBS is the main H2S producing enzyme in brain. A recent study showed that 3-mercaptopyruvate sulfurtransferase (3MST) in combination with cysteine aminotransferase (CAT) also produces H2S from cysteine. In addition, 3MST is localized to neurons, and the levels of bound sulfane sulfur, the precursor of H2S, are greatly increased in the cells expressing 3MST and CAT but not increased in cells expressing functionally defective mutant enzymes . Numerous studies showed that H2S has anti-oxidant, anti-apoptotic effects in neuron and glial cells [8, 9]. H2S induces alterations in Ca2+ in astrocytes and microglia [10, 11], suggesting it may have anti-inflammatory properties. H2S produces an anti-inflammatory effect in lipopolysaccharide (LPS)-induced inflammation in both primary cultured microglia and immortalized murine BV-2 microglial cells . The levels of S-adenosylmethionine (SAM), an activator of CBS, are lower in AD brains than that in the brains of normal individuals . Another study showed that H2S is an endogenous anti-inflammatory and neuroprotective agent, and H2S releasing drugs may have therapeutic potential in neurodegenerative disorders of aging such as AD and Parkinson’s disease (PD) .
The above-mentioned roles of H2S raise the possibility that H2S may be associated with the pathology of AD. However, so far, a possible role for H2S as an anti-inflammatory agent in rat model of AD has not been extensively evaluated. The focus of the present study was to elucidate the effect of NaHS on cognitive impairment and neuroinflammatory changes in rat model of AD as well as possible mechanisms of action.
Surgery and drug administration
Healthy male Wistar rats (220 to 250 g) were randomly divided into four groups (n = 56 for each group): sham (control) group, sham + NaHS group, Aβ1-40 group, and Aβ1-40 + NaHS group. Rats in the Aβ1-40 + NaHS group were administered with NaHS (Sigma, USA) by intraperitoneal injection (i.p.) at a dose of 5 mg/kg once daily, 3 days before surgery and thereafter continuously for 9 days[15, 16]. Three days after treatment with NaHS, anesthesia was induced by chloral hydrate (35 mg/100 g weight, i.p.). Aβ1-40 (10 nmol in 10 μL of sterile PBS) was incubated at 37°C for 1 week to induce the aggregation of Aβ1-40. The aggregated Aβ1-40 and vehicle was injected slowly over 10 min into the right dentate gyrus (DG) of rats at the following coordinates: anterior/posterior −3.3 mm, media/lateral 2.0 mm, and dorsal/ventral −3.3 mm ventral to the skull surface. The rectal temperature was maintained at 36°C to 37°C for all animals throughout the experiment. All animal experiments were performed according to protocols approved by the local animal care committee.
Morris water maze
The Morris water maze task was evaluated as previously described  with slight modification. Trials were performed during days 8 to 11 after the injection of Aβ1-40. The task for all of the animals in each trial consisted of finding a hidden clear plastic platform (10 cm diameter) that was placed 50 cm away from the wall of the water maze (150 cm in diameter, 60 cm in depth) and 1 cm below the water. The platform remained in the same position for all trials and sessions. The starting quadrant was randomized every day, with all animals using the same order. The animals were faced towards the pool wall before being released. The time required to reach the hidden platform and the swimming speed were recorded. The animals were allowed to rest 30 s on the platform between trials. If an animal failed to reach the platform in 120 s, it was manually guided to the platform. Each animal underwent two sessions (each contains four trials: NE; NW; SE; SW) per day for 4 consecutive days. Before surgery, animals were screened (without platform in the pool) for any rats that could not swim. Seven days after the injection of Aβ1-40, animals were examined as above.
Immunohistochemistry and TUNEL staining
Immunohistochemistry was performed on the eighth day after Aβ1-40 injection. After being microwaved for 5 min and washed three times in PBS (pH 7.4), sections were successively incubated with 0.3% H2O2 in methanol for 10 min, 10% normal goat serum in PBS for 20 min, and primary antibody (anti-GFAP, anti-OX42, Millipore, USA) dissolved in 2% normal goat serum, 0.3% Triton X-100, 0.05% NaN3 in PBS at 4°C overnight, and then 37°C for 30 min. After rinsing three times in PBS, the sections were incubated with biotinylated anti-mouse or anti-rabbit secondary antibodies (Boster, China) in PBS for 30 min at 37°C, then incubated with avidin-biotin-peroxidase solution (SABC kit, Boster, China) and colorized with a DAB kit (Boster, China).
To detect cells undergoing apoptosis, TUNEL technique was performed according to the manufacturer’s protocol supplied within the in situ Cell Death Detection Kit. The sections were immersed in 3% H2O2 for inactivation of endogenous hydrogen peroxidase activity. After rinsing with PBS, the sections were incubated with proteinase K solution at 37°C for 20 min to enhance the permeability. Then they were incubated for 60 min at 37°C with TUNEL reaction mixture and again incubated for 30 min at 37°C with converter-POD. The sections were rinsed in PBS, incubated for 10 min with DAB substrate solution and rinsed again with PBS. Counter staining was done with 0.5% methyl green. Positive and negative controls were carried out on slides from the same block. For TUNEL staining, 10 fields were chosen from each group and the percent of TUNEL-positive cells were calculated according to this relation: % TUNEL-positive neurons = (TUNEL-positive neurons (brown)/TUNEL-positive neurons (brown) + normal neurons (green)) × 100.
Measurement of pro-inflammatory cytokines
Hippocampal samples were homogenized in 10 wet weight volumes of TBS, pH 8.0, containing a cocktail of protease inhibitors (20 mg/mL each of pepstatin A, aprotinin, phosphoramidon, and leupeptin, 0.5 mM PMSF, and 1 mM EGTA). Samples were sonicated briefly (10 W, 2 × 5 s) and centrifuged at 100,000 × g for 20 min at 4°C. The soluble fraction (supernatant) was used for IL-1β and TNF-α ELISAs (R&D Systems, USA).
Real time RT-PCR analysis
Expressions of genes were further confirmed by real time PCR. Total RNA from hippocampus tissues were extracted using TriZol reagent (Invitrogen). Reverse transcription was performed with an ExScript RT Reagent Kit (Takara Bio Inc., China). Real-time PCR analysis was undertaken using SYBR Premix Ex Taq (Takara Bio Inc., China). The primers sequences for IL-1β were 5′-GCT GTG GCA GCT ACC TAT GTC TTG-3′ (sense) and 5′-AGG TCG TCA TCA TCC CAC GAG-3′ (antisense). The primer sequences for TNF-α were 5′-GTG ATC GGT CCC AAC AAG GA-3′ (sense) and 5′-CTC CCA CCC TAC TTT GCT TGT G-3′ (antisense). The primer sequences for β-actin were 5′-TGA CAG G TG CAG AAG GAG A-3′ (sense) and 5′-TAG AGC CAC CAA TCC ACA CA-3′ (antisense). The real-time PCR conditions were as follows: initial denaturation at 95°C for 10 s followed by 39 cycles of 95°C for 5 s and 60°C for 20 s. The expression levels of the genes were quantified by comparison with a standard curve and normalized relative to levels of ß-actin.
Western blot analysis
Expression of Aβ1-40, phospho-p38 MAPK, phospho-p65 NF-κB, and phospho-JNK was analyzed by western blot. Thirty μg protein of each sample was heated at 100°C for 5 min with a loading buffer containing 0.125 M Tris–HCl (pH 6.8), 20% glycerol, 4% SDS, 10% mercaptoethanol, and 0.002% bromophenol blue. It was then separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using 10% acrylamide gels. The proteins were transferred onto PVDF membranes (pore size, 0.45 μm). Blotting membranes were incubated with 3% bovine serum albumin (BSA) in tris buffered saline with tween (TBST) (10 mmol/L Tris (pH 7.5), 150 mmol/L NaCl, 0.05% Tween-20) and probed with corresponding primary antibodies (anti-Aβ1-40, anti-phospho-p65 NF-κB, anti-phospho-p38 MAPK, and anti-phospho-JNK, CST, USA) at 4°C overnight. After incubation with horseradish peroxidase-coupled secondary antibodies for 2 h at room temperature, bands were quantitated by densitometry (UVP Upland, CA).
All values were expressed as the mean ± standard error of the mean (SEM). For the behavioral experiments, the escape latency during the training tests was determined by two-way repeated factor analysis of variance (ANOVA) with Student-Newman-Keuls tests. All other assessments were analyzed using a one-way ANOVA followed by Student-Newman-Keul’s or Dunnett’s post-hoc analysis. In all cases, P < 0.05 was considered significant.
NaHS prevented Aβ-induced impairment of spatial learning
In the probe trial of the Morris water maze test, Aβ1-40 had a significant effect on the time and distance in target quadrant compared with the sham group (P < 0.01). Compared with the Aβ1-40-injected group, NaHS + Aβ1-40 rats displayed more time and distance swimming in the target quadrant (P < 0.05) (Figure 1C, D).
NaHS suppressed Aβ1-40-induced apoptosis in Aβ1-40-injection rat model
NaHS lowered protein levels of Aβ1-40 in the hippocampus of rats
NaHS decreased Aβ-induced astrocytic and microglial response
NaHS attenuated Aβ-induced increases in the levels of cytokine production and mRNA in the hippocampus
The effects of NaHS on the mRNA of IL-1β and TNF-α were investigated by real-time RT-PCR. Compared with the sham group, injection of Aβ1-40 in the hippocampus highly increased the mRNA of IL-1β and TNF-α, which were approximately 4.7-fold and 2.4-fold, respectively (P < 0.01, Figure 5C, D). However, compared to the Aβ1-40 group, treatment with NaHS significantly decreased the mRNA expressions of these selected genes (P < 0.01, Figure 5C, D).
NaHS decreased the activation of phospho-p38 MAPK and phospho-p65 NFκB, but not phospho-JNK in the hippocampus
The deposition of Aβ in brain areas involved in cognitive functions is assumed to initiate a pathological cascade that results in synaptic dysfunction, synaptic loss, and neuronal death . It has been proposed that Aβ1-40 aggregates play an important role in the pathogenesis of AD . Numerous reports have showed that the injection of Aβ1-40 into rat hippocampus provides an effective model to mimic some of the pathologic and behavioral changes of AD [24–26]. In our study, we demonstrated that Aβ1-40 injection could induce memory deficits and NaHS treatment could also effectively ameliorate Aβ-induced impairment of spatial learning.
Memory impairment in Aβ-injected rats was associated with a significant reduction in apoptosis. Apoptosis has been consistently implicated in Aβ-induced neuronal damage in vitro, in animal models of AD, and also postmortem studies of AD brain [27–29]. The mechanisms underlying Aβ-mediated neurotoxicity still remain to be elucidated, but mounting evidence suggests the involvement of Aβ-induced neuroinflammatory in the disease process with AD. Studies have shown that Aβ induces the production of neuroinflammatory molecules, which may contribute to the pathogenesis of numerous neurodegenerative diseases [30–32]. However, lots of studies have also demonstrated that anti-inflammatory compounds could exhibit neuroprotective effects in damaged brain cells [33–35]. Central administration of NaHS prevented Aβ1-40-evoked apoptosis. Decrease in TUNEL-positive neurons may stem from its general suppression of the neuroinflammatory context in the Aβ1-40-inflicted hippocampus, thus attenuating the inflammatory cell death.
Evidence suggests that inflammatory reaction induced by Aβ in the AD involves astrogliosis, microgliosis, cytokine elevation, and changes in acute phase proteins [22, 36]. Activated astrocytes and microglia can secrete inflammatory cytokines and mediators that promote the formation of Aβ and NFTs through numerous signal transduction pathways . In the brains of AD rats, the production of IL-1β and TNF-α play an important role in augmenting inflammatory reaction and formation of Aβ . Several reports have provided evidence demonstrating a role for IL-1β in the etiology of AD based largely on the finding that IL-1β expression in different brain areas in AD and also in the cerebrospinal fluid of AD patients [39, 40]. Consistently, the injection of Aβ increases the hippocampal mRNA expression of both TNF-α and inducible nitric oxide synthase (iNOS), of which the former was stronger, and the knock-out of TNF-α (TNF-α (−/−)) in mouse prevented the increase of iNOS mRNA in the hippocampus and the impairment of recognition memory in mice induced by Aβ . It has been proposed that elevated levels of pro-inflammatory cytokines, including TNF-α, may inhibit phagocytosis of Aβ in AD brains thereby hindering efficient plaque removal by resident microglia . In our studies, we demonstrated that the hippocampus of the Aβ1-40 group had the activation of astrogliosis and microgliosis as well as the strong increase of IL-1β and TNF-α compared with the sham group, indicating that the two inflammatory cytokines were involved in the inflammatory response in AD rats.
Our results demonstrated that NaHS treatment decreased Aβ1-40-induced astrocytic and microglial response as well as inflammatory cytokines expression. A previous study showed that H2S was synthesized in brain primarily by the enzyme CBS, and that astrocytes were the most active producers of H2S, with much smaller quantities being generated by microglia . H2S production is suppressed by inflammatory stimulation of microglia and astrocytes, and this suppression reduces the natural anti-inflammatory effect of H2S . H2S has been reported to exhibit marked anti-inflammatory activity in LPS-induced lung, liver, and kidney tissue inflammatory damage in the mouse . Another result reveals that H2S releasing NSAIDS S-aspirin and S-diclofenac attenuates the neuroinflammation induced by activation of glia . Administration of NaHS significantly attenuates LPS-induced cognitive impairment through reducing the overproduction of proinflammatory mediators, and accompanied by an increase of H2S levels . However, there is no direct evidence that H2S attenuates inflammatory initiated neuronal death, which is closely associated with the pathogenesis of several neurodegenerative diseases including AD.
To further understand the molecular mechanisms of the effects of NaHS on the expressions of IL-1β and TNF-α, the expressions of phospho-p38 MAPK, phospho-p65 NF-κB, and phospho-JNK were analyzed by western blot. Numerous studies demonstrate that injection of Aβ into the hippocampus, cortex, and nucleus basalis induces the activity of p38 MAPK, NF-κB, and JNK in rat [47–50]. p38 MAPK activation has been implicated in the pathogenesis of AD, and significant increase of MAPK kinase 6 (MKK6), one of the upstream activators of p38 MAPK, is observed in hippocampal and cortical regions of individuals with AD compared with age-matched controls . Chronic exposure of human microglia to Aβ1-42 led to enhanced p38 MAPK expression . NF-κB is known to upregulate the expressions of cytokines, chemokines, adhesion molecules, acute phase proteins, and inducible effector enzymes. NF-κB is composed of several protein subunits, among which p65 has been extensively studied. In AD brains, p65 NF-κB immunoreactivity is greater in neurons and astrocytes surrounding amyloid plaques [52, 53]. Additionally, it has been reported that Aβ stimulation leads to p65 NF-κB activation in cultured neurons and glia . One study has revealed that increased hippocampal IL-1βconcentration, paralleled by increased JNK activation in AD brain . The activation of JNK has been described in cultured neurons after Aβ exposure, and their inhibition attenuates Aβ toxicity [49, 55]. Corroborating these findings, the present results show that increased hippocampal concentration of inflammatory cytokines stimulated by Aβ is accompanied by phosphorylation of p38 MAPK, p65 NF-κB, and JNK.
Our data also suggest that the effects of H2S against the released levels of pro-inflammatory cytokines such as IL-1β and TNF-α may include the capability of this gas to reduce the levels of phospho-p38 MAPK and phospho-p65 NF-κB but not phospho-JNK. This is consistent with reports that S-diclofenac decreases the activation of NFκB and other pro-inflammatory cytokines in rat plasma and liver homogenates  and that NaHS attenuates LPS-induced inflammation by inhibition of p38 MAPK and p65 NF-κB in rodent microglia and rat [12, 46].
In conclusion, our results clearly demonstrated that: (1) a single injection of Aβ1-40 into the hippocampus produced cognitive impairment in rats, apoptosis, and the glial response, with concomitant production of IL-1β and TNF-α, and these effects occurred via activation of p38 MAPK, p65 NF-κB, and phospho-JNK in rat’s hippocampus; and (2) pretreatment with NaHS significantly attenuated Aβ1-40-induced cognitive deficits, apoptosis, and the glial response, with concomitant inhibitions of IL-1β and TNF-α production, as well as repressed Aβ1-40-induced activation of p38 MAPK and p65 NF-κB.
This research was co-financed by grants from Natural Science Foundation of China (No. 30900728), Medical Scientific Research Foundation of Guangdong Province (No. A2010228), Science Foundation of Education Bureau of Guangzhou City (No. 10A156).
- Mildner A, Schlevogt B, Kierdorf K, Böttcher C, Erny D, Kummer MP, Quinn M, Brück W, Bechmann I, Heneka MT, Priller J, Prinz M: Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer’s disease. J Neurosci 2011, 31:11159–11171.View ArticlePubMedGoogle Scholar
- Eikelenboom P, van Exel E, Hoozemans JJ, Veerhuis R, Rozemuller AJ, van Gool WA: Neuroinflammation-an early event in both the history and pathogenesis of Alzheimer’s disease. Neurodegener Dis 2010, 7:38–41.View ArticlePubMedGoogle Scholar
- Seabrook TJ, Jiang L, Maier M, Lemere CA: Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. Glia 2006, 53:776–782.View ArticlePubMedGoogle Scholar
- Weldon DT, Rogers SD, Ghilard JR, Finke MP, Cleary JP, O’Hare E, Esler WP, Maggio JE, Mantyh PW: Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J Neurosci 1998, 18:2161–2173.PubMedGoogle Scholar
- Potter PE: Investigational medications for treatment of patients with Alzheimer disease. J Am Osteopath Assoc 2010, Suppl 8:27–36.Google Scholar
- Kamoun P: Endogenous production of hydrogen sulfide in mammals. Amino Acids 2004, 26:243–254.View ArticlePubMedGoogle Scholar
- Shibuya N, Tanaka M, Yoshida M, Ogasawara Y, Togawa T, Ishii K, Kimura H: 3-Mercaptopyruvate sulfurtransferase produces hydrogen sulfide and bound sulfane sulfur in the brain. Antioxid Redox Signal 2009, 11:703–714.View ArticlePubMedGoogle Scholar
- Kimura Y, Kimura H: Hydrogen sulfide protects neurons from oxidative stress. FASEB J 2004, 18:1165–1167.PubMedGoogle Scholar
- Yin WL, He JQ, Hu B, Jiang ZS, Tang XQ: Hydrogen sulfide inhibits MPP(+)-induced apoptosis in PC12 cells. Life Sci 2009, 85:269–275.View ArticlePubMedGoogle Scholar
- Lee SW, Hu YS, Hu LF, Lu Q, Dawe GS, Moore PK, Wong PT, Bian JS: Hydrogen sulphide regulates calcium homeostasis in microglial cells. Glia 2006, 54:116–124.View ArticlePubMedGoogle Scholar
- Nagai Y, Tsugane M, Oka J, Kimura H: Hydrogen sulfide induces calcium waves in astrocytes. FASEB J 2004, 18:557–559.PubMedGoogle Scholar
- Hu LF, Wong PT, Moore PK, Bian JS: Hydrogen sulfide attenuates lipopolysaccharide induced inflammation by inhibition of p38 mitogen-activated protein kinase in microglia. J Neurochem 2007, 100:1121–1128.View ArticlePubMedGoogle Scholar
- Morrison LD, Smith DD, Kish SJ: Brain S-adenosylmethionine levels are severely decreased in Alzheimer’s disease. J Neurochem 1996, 67:1328–1331.View ArticlePubMedGoogle Scholar
- Lee M, Schwab C, Yu S, McGeer E, McGeer PL: Astrocytes produce the antiinflammatory and neuroprotective agent hydrogen sulfide. Neurobiol Aging 2009, 30:1523–1534.View ArticlePubMedGoogle Scholar
- Gong QH, Wang Q, Pan LL, Liu XH, Huang H, Zhu YZ: Hydrogen sulfide attenuates lipopolysaccharide-induced cognitive impairment: A pro-inflammatory pathway in rats. Pharmacol Biochem BE 2010, 96:52–58.View ArticleGoogle Scholar
- Qu K, Chen CP, Halliwell B, Moore PK, Wong PT: Hydrogen sulfide is a mediator of cerebral ischemic damage. Stroke 2006, 37:889–893.View ArticlePubMedGoogle Scholar
- Huang HJ, Liang KC, Chen CP, Chen CM, Hsieh-Li HM: Intrahippocampal administration of A beta(1–40) impairs spatial learning and memory in hyperglycemic mice. Neurobiol Learn Mem 2007, 87:483–494.View ArticlePubMedGoogle Scholar
- Morris R: Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984, 11:47–60.View ArticlePubMedGoogle Scholar
- Srivareerat M, Tran TT, Salim S, Aleisa AM, Alkadhi KA: Chronic nicotine restores normal Aβ levels and prevents short-term memory and E-LTP impairment in Aβ rat model of Alzheimer’s disease. Neurobiol Aging 2011, 32:834–844.View ArticlePubMedGoogle Scholar
- Bagheri M, Roghani M, Joghataei MT, Mohseni S: Genistein inhibits aggregation of exogenous amyloid-beta1–40 and alleviates astrogliosis in the hippocampus of rats. Brain Res 2012, 1429:145–154.View ArticlePubMedGoogle Scholar
- Miguel-Hidalgo JJ, Cacabelos R: Beta-amyloid(1–40)-induced neurodegeneration in the rat hippocampal neurons of the CA1 subfield. Acta Neuropathol 1998, 95:455–465.View ArticlePubMedGoogle Scholar
- Walsh DM, Selkoe DJ: Deciphering the molecular basis of memory failure in Alzheimer’s disease. Neuron 2004, 44:181–193.View ArticlePubMedGoogle Scholar
- Hashimoto T, Adams KW, Fan Z, McLean PJ, Hyman BT: Characterization of oligomer formation of amyloid-beta peptide using a split-luciferase complementation assay. J Biol Chem 2011, 286:27081–27091.View ArticlePubMedPubMed CentralGoogle Scholar
- Shin RW, Ogino K, Kondo A, Saido TC, Trojanowski JQ, Kitamoto T, Tateishi J: Amyloid beta-protein (Abeta) 1–40 but not Abeta1–42 contributes to the experimental formation of Alzheimer disease amyloid fibrils in rat brain. J Neurosci 1997, 17:8187–8193.PubMedGoogle Scholar
- Yamaguchi Y, Miyashita H, Tsunekawa H, Mouri A, Kim HC, Saito K, Matsuno T, Kawashima S, Nabeshima T: Effects of a novel cognitive enhancer, spiro[imidazo-[1,2-a] pyridine −3,2- indan]-2(3H)-one (ZSET1446), on learning impairments induced by amyloid-beta1–40 in the rat. J Pharmacol Exp Ther 2006, 317:1079–1087.View ArticlePubMedGoogle Scholar
- Zou K, Kim D, Kakio A, Byun K, Gong JS, Kim J, Kim M, Sawamura N, Nishimoto S, Matsuzaki K, Lee B, Yanagisawa K, Michikawa M: Amyloid beta-protein (Abeta)1–40 protects neurons from damage induced by Abeta1–42 in culture and in rat brain. J Neurochem 2003, 87:609–619.View ArticlePubMedGoogle Scholar
- Yu Y, Zhou L, Sun M, Zhou T, Zhong K, Wang H, Liu Y, Liu X, Xiao R, Ge J, Tu P, Fan DS, Lan Y, Hui C, Chui D: Xylocoside G reduces amyloid-β induced neurotoxicity by inhibiting NF-κB signaling pathway in neuronal cells. J Alzheimers Dis 2012, 30:263–275.PubMedGoogle Scholar
- Hwang DY, Chae KR, Kang TS, Hwang JH, Lim CH, Kang HK, Goo JS, Lee MR, Lim HJ, Min SH, Cho JY, Hong JT, Song CW, Paik SG, Cho JS, Kim YK: Alterations in behavior, amyloid beta-42, caspase-3, and Cox-2 in mutant PS2 transgenic mouse model of Alzheimer’s disease. FASEB J 2002, 6:805–813.View ArticleGoogle Scholar
- Dragunow M, Faull RL, Lawlor P, Beilharz EJ, Singleton K, Walker EB, Mee E: In situ evidence for DNA fragmentation in Huntington’s disease striatum and Alzheimer’s disease temporal lobes. Neuroreport 1995, 6:1053–1057.View ArticlePubMedGoogle Scholar
- Tweedie D, Ferguson RA, Fishman K, Frankola KA, Van Praag H, Holloway HW, Luo W, Li Y, Caracciolo L, Russo I, Barlati S, Ray B, Lahiri DK, Bosetti F, Greig NH, Rosi S: Tumor necrosis factor-α synthesis inhibitor 3,6′-dithiothalidomide attenuates markers of inflammation. Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer’s disease. J Neuroinflammation 2012, 9:106.View ArticlePubMedPubMed CentralGoogle Scholar
- Liu S, Liu Y, Hao W, Wolf L, Kiliaan AJ, Penke B, Rübe CE, Walter J, Heneka MT, Hartmann T, Menger MD, Fassbender K: TLR2 is a primary receptor for Alzheimer’s amyloid β peptide to trigger neuroinflammatory activation. J Immunol 2012, 188:1098–1107.View ArticlePubMedGoogle Scholar
- Maeda J, Ji B, Irie T, Tomiyama T, Maruyama M, Okauchi T, Staufenbiel M, Iwata N, Ono M, Saido TC, Suzuki K, Mori H, Higuchi M, Suhara T: Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer’s disease enabled by positron emission tomography. J Neurosci 2007, 27:10957–10968.View ArticlePubMedGoogle Scholar
- Zhu LH, Bi W, Qi RB, Wang HD, Wang ZG, Zeng Q, Zhao YR, Lu DX: Luteolin reduces primary hippocampal neurons death induced by neuroinflammation. Neurol Res 2011, 33:927–934.View ArticlePubMedGoogle Scholar
- Lee JY, Cho E, Ko YE, Kim I, Lee KJ, Kwon SU, Kang DW, Kim JS: Ibudilast, a phosphodiesterase inhibitor with anti-inflammatory activity, protects against ischemic brain injury in rats. Brain Res 2012, 1431:97–106.View ArticlePubMedGoogle Scholar
- Liu T, Jin H, Sun QR, Xu JH, Hu HT: The neuroprotective effects of tanshinone IIA on β-amyloid-induced toxicity in rat cortical neurons. Neuropharmacology 2010, 59:595–604.View ArticlePubMedGoogle Scholar
- Franciosi S, Ryu JK, Choi HB, Radov L, Kim SU, McLarnon JG: Broad-spectrum effects of 4-aminopyridine to modulate amyloid beta1–42-induced cell signaling and functional responses in human microglia. J Neurosci 2006, 26:11652–11664.View ArticlePubMedGoogle Scholar
- Peila R, Launer LJ: Inflammation and dementia: epidemiologic evidence. Acta Neurol Scand Suppl 2006, 185:102–106.View ArticlePubMedGoogle Scholar
- Morales I, Farías G, Maccioni RB: Neuroimmunomodulation in the pathogenesis of Alzheimer’s disease. Neuroimmunomodulation 2010, 17:202–204.View ArticlePubMedGoogle Scholar
- Angelopoulos P, Agouridaki H, Vaiopoulos H, Siskou E, Doutsou K, Costa V, Baloyiannis SI: Cytokines in Alzheimer’s disease and vascular dementia. Int J Neurosci 2008, 118:1659–1672.View ArticlePubMedGoogle Scholar
- Forlenza OV, Diniz BS, Talib LL, Mendonça VA, Ojopi EB, Gattaz WF, Teixeira AL: Increased serum IL-1beta level in Alzheimer’s disease and mild cognitive impairment. Dement Geriatr Cogn Disord 2009, 28:507–512.View ArticlePubMedGoogle Scholar
- Alkam T, Nitta A, Mizoguchi H, Saito K, Seshima M, Itoh A, Yamada K, Nabeshima T: Restraining tumor necrosis factor-alpha by thalidomide prevents the amyloid beta-induced impairment of recognition memory in mice. Behav Brain Res 2008, 189:100–106.View ArticlePubMedGoogle Scholar
- Koenigsknecht-Talboo J, Landreth GE: Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci 2005, 25:8240–8249.View ArticlePubMedGoogle Scholar
- Abe K, Kimura H: The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci 1996, 16:1066–1071.PubMedGoogle Scholar
- Li L, Bhatia M, Zhu YZ, Zhu YC, Ramnath RD, Wang ZJ, Anuar FB, Whiteman M, Salto-Tellez M, Moore PK: Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse. FASEB J 2005, 19:1196–1198.PubMedGoogle Scholar
- Lee M, Sparatore A, Del Soldato P, McGeer E, McGeer PL: Hydrogen sulfide-releasing NSAIDs attenuate neuroinflammation induced by microglial and astrocytic activation. Glia 2010, 58:103–113.View ArticlePubMedGoogle Scholar
- Gong QH, Wang Q, Pan LL, Liu XH, Huang H, Zhu YZ: Hydrogen sulfide attenuates lipopolysaccharide-induced cognitive impairment: a pro-inflammatory pathway in rats. Pharmacol Biochem Behav 2010, 96:52–58.View ArticlePubMedGoogle Scholar
- Giovannini MG, Scal C, Prosperi C, Bellucci A, Vannucchi MG, Rosi S, Pepeu G, Casamenti F: Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol Dis 2002, 11:257–274.View ArticlePubMedGoogle Scholar
- Ji C, Aisa HA, Yang N, Li Q, Wang T, Zhang L, Qu K, Zhu HB, Zuo PP: Gossypium herbaceam extracts inhibited NF-kappaB activation to attenuate spatial memory impairment and hippocampal neurodegeneration induced by amyloid-beta in rats. J Alzheimers Dis 2008, 14:271–283.PubMedGoogle Scholar
- Minogue AM, Lynch AM, Loane DJ, Herron CE, Lynch MA: Modulation of amyloid-beta-induced and age-associated changes in rat hippocampus by eicosapentaenoic acid. J Neurochem 2007, 103:914–926.View ArticlePubMedGoogle Scholar
- Wang C, Li J, Liu Q, Yang R, Zhang JH, Cao YP, Sun XJ: Hydrogen-rich saline reduces oxidative stress and inflammation by inhibit of JNK and NF-κB activation in a rat model of amyloid-beta-induced Alzheimer’s disease. Neurosci Lett 2011, 491:127–132.View ArticlePubMedGoogle Scholar
- Zhu X, Rottkamp CA, Hartzler A, Sun Z, Takeda A, Boux H, Shimohama S, Perry G, Smith MA: Activation of MKK6, an upstream activator of p38, in Alzheimer’s disease. J Neurochem 2001, 79:311–318.View ArticlePubMedGoogle Scholar
- Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kaltschmidt C: Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci U S A 1997, 94:2642–2647.View ArticlePubMedPubMed CentralGoogle Scholar
- Kitamura Y, Shimohama S, Ota T, Matsuoka Y, Nomura Y, Taniguchi T: Alteration of transcription factors NF-kappaB and STAT1 in Alzheimer’s disease brains. Neurosci Lett 1997, 237:17–20.View ArticlePubMedGoogle Scholar
- Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, Yi S, Mucke L, Gan L: SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem 2005, 280:40364–40374.View ArticlePubMedGoogle Scholar
- Ebenezer PJ, Weidner AM, LeVine H, Markesbery WR, Murphy MP, Zhang L, Dasuri K, Fernandez-Kim SO, Bruce-Keller AJ, Gavilán E, Keller JN: Neuron specific toxicity of oligomeric amyloid-β: role for JUN-kinase and oxidative stress. J Alzheimers Dis 2010, 22:839–848.PubMedPubMed CentralGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.